Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon Congleton
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 0.68
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.58
Financials
Net Income
$-241.07MEBITDA
$-241.07M-32457.9%Free Cash Flow
$-32.56MEPS (diluted)
$-2.85Shares Outstanding (diluted)
84.73M+1574.5%Operating Expenses
$246.04MCash & Debt
$661.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-154.65M | $-2.29 |
| 2024 | $0.00 | $-177.81M | $-3.66 |
| 2023 | $0.00 | $-71.90M | $-1.99 |
| 2022 | $0.00 | $-29.80M | $-5.77 |
| 2021 | $0.00 | $-19.41M | $-3.89 |
| 2020 | $0.00 | $-3.43M | $-0.74 |
Valuation
MLYShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+15.38%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·3d ago·Neutral
…w Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrost…
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
…ys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2…
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…te-Breaking Presentation at American Heart Association Scientific Sessions 2026 RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety da…
View source ↗ - Newsseekingalpha.com·32d ago·Positive
… to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with Baxfendy, MLYS's focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fa…
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Mineralys Therapeutics Q2 Earnings Call Highlights Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.53 per share
Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-2.85 vs $-0.55miss
- Wed, May 6$-0.47 vs $-0.51beat
- Thu, Mar 12$-0.40 vs $-0.52beat
- Mon, Nov 10$-0.52 vs $-0.66beat
- Tue, Aug 12$-0.66 vs $-0.78beat
- Mon, May 12$-0.79 vs $-1.02beat
Estimates and results for MLYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MLYS officers and directors.
- Bought
- $8.8m
- Sold
- $15.6m
2 trades
34 trades
- Congleton Jonsold
- Slingsby Brian Taylorsold
- Warren Ericsold
- Karydas Daphnesold
- Warren Ericsold
- Rodman David Malcomsold
- Warren Ericsold
- Rodman David Malcomsold
64 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MLYS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.